Effects and Intervention Strategies of Second-Generation Antipsychotics on Metabolism of Patients with Bipolar Disorder

Xinwei Li

doi:10.54097/0hrwrt87

Authors

Xinwei Li

DOI:

https://doi.org/10.54097/0hrwrt87

Keywords:

Bipolar Disorder, Second-generation, Metabolic, Adverse Effects, Obesity, Side Effects, Intervention, Strategies, Treatment

Abstract

Bipolar Disorder (BD) is a chronic mental illness characterized by alternating manic-depressive episodes, with 0.53% as its global lifetime prevalence. Clinical treatment needs to follow the principle of long-term management based on medications. During the manic episodes of bipolar disorder patients, both first-generation antipsychotics (e.g., chlorpromazine and haloperidol) and second-generation antipsychotics (e.g., olanzapine, clozapine, quetiapine, and risperidone) can provide effective therapeutic outcomes. However, these medications may also negatively impact physiological indicators such as blood glucose, blood lipid, and blood pressure through mechanisms like drug-induced neuroregulation, insulin resistance, and mitochondrial damage. This metabolic disorder may increase the risk of developing chronic diseases such as coronary heart disease and type 2 diabetes. This review focuses on the metabolic disorders caused by the use of second-generation antipsychotics alone or in combination with mood stabilizers (lithium salts/valproate). It systematically evaluates the intervention efficacy of hypoglycemic/lipid-regulating drugs and integrates traditional Chinese medicine-assisted treatment regimens. The research results provide multi-dimensional management strategies for the clinical prevention and treatment of antipsychotic-related metabolic abnormalities.

Downloads

Download data is not yet available.

References

[1] Association, S. C. G. o. P. B. o. C. M. (2020). Chinese expert consensus on the management of metabolic syndrome in schizophrenic patients. Chinese Journal of Psychiatry(1), 3-10.

[2] Carolan, A., Hynes-Ryan, C., Agarwal, S. M., Bourke, R., Cullen, W., Gaughran, F., Hahn, M. K., Krivoy, A., Lally, J., & Leucht, S. (2024). Metformin for the prevention of antipsychotic-induced weight gain: guideline development and consensus validation. Schizophrenia Bulletin, sbae205.

[3] Chen, X., Yu, Y., Zheng, P., Jin, T., He, M., Zheng, M., Song, X., Jones, A., & Huang, X.-F. (2020). Olanzapine increases AMPK-NPY orexigenic signaling by disrupting H1R-GHSR1a interaction in the hypothalamic neurons of mice. Psychoneuroendocrinology, 114, 104594.

[4] Chokhawala, K., & Stevens, L. (2020). Antipsychotic Medications StatPearls. Treasure Island (FL).

[5] Collaborators, G. M. D. (2022). Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Psychiatry, 9(2), 137-150.

[6] Contreras-Shannon, V., Heart, D. L., Paredes, R. M., Navaira, E., Catano, G., Maffi, S. K., & Walss-Bass, C. (2013). Clozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cells. PloS one, 8(3), e59012.

[7] Correll, C. U. (2007). Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. Journal of the American Academy of Child & Adolescent Psychiatry, 46(6), 687-700.

[8] Daumit, G. L., Goff, D. C., Meyer, J. M., Davis, V. G., Nasrallah, H. A., McEvoy, J. P., Rosenheck, R., Davis, S. M., Hsiao, J. K., & Stroup, T. S. (2008). Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophrenia research, 105(1-3), 175-187.

[9] Delgado, A., Velosa, J., Zhang, J., Dursun, S. M., Kapczinski, F., & de Azevedo Cardoso, T. (2020). Clozapine in bipolar disorder: A systematic review and meta-analysis. Journal of psychiatric research, 125, 21-27.

[10] Dipta, P., Sarsenbayeva, A., Shmuel, M., Forno, F., Eriksson, J. W., Pereira, M. J., Abalo, X. M., Wabitsch, M., Thaysen-Andersen, M., & Tirosh, B. (2021). Macrophage-derived secretome is sufficient to confer olanzapine-mediated insulin resistance in human adipocytes. Comprehensive Psychoneuroendocrinology, 7, 100073.

[11] Du, Y. J. (2011). Clinical observation of electroacupuncture in the treatment of obesity caused by antipsychotics. China Modern Medicine, 18(10), 85-86.

[12] Fitzgerald, I., O'Connell, J., Keating, D., Hynes, C., McWilliams, S., & Crowley, E. K. (2022). Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology. BMJ Ment Health, 25(1), 15-22.

[13] Geddes, J. R., & Miklowitz, D. J. (2013). Treatment of bipolar disorder. The Lancet, 381(9878), 1672-1682.

[14] Gill, H., Gill, B., El‐Halabi, S., Chen‐Li, D., Lipsitz, O., Rosenblat, J. D., Van Rheenen, T. E., Rodrigues, N. B., Mansur, R. B., & Majeed, A. (2020). Antidepressant medications and weight change: a narrative review. Obesity, 28(11), 2064-2072.

[15] Goldstein, B. I., Carnethon, M. R., Matthews, K. A., McIntyre, R. S., Miller, G. E., Raghuveer, G., Stoney, C. M., Wasiak, H., & McCrindle, B. W. (2015). Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 132(10), 965-986.

[16] Grunze, H., Schaefer, M., Scherk, H., Born, C., & Preuss, U. W. (2021). Comorbid bipolar and alcohol use disorder—a therapeutic challenge. Frontiers in Psychiatry, 12, 660432.

[17] He, Y. O., LUO, Y. T., YANG, X. . (2022). Clinical efficacy of sodium valproate sustained-release tablets combined with olanzapine in the treatment of female bipolar disorder and its effect on glucose and lipid metabolism in patients. Chinese Journal of Clinical Rational Drug Use, 15(33), 56-58.

[18] Heffner, J. L., Strawn, J. R., DelBello, M. P., Strakowski, S. M., & Anthenelli, R. M. (2011). The co‐occurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations. Bipolar disorders, 13(5‐6), 439-453.

[19] Hesapcioglu, S. T., Kasak, M., Abursu, H., Kafali, S., Ceylan, M. F., & Akyol, M. (2024). A systematic review and network meta-analysis on comparative efficacy, acceptability, and safety of treatments in acute bipolar mania in youths. Journal of Affective Disorders, 349, 438-451.

[20] Hu, Y. R. (2023). Correlation analysis of antiseizure drugs with lipid metabolism and atherosclerosis in patients with epilepsy Xinjiang Medical University]. Urumqi.

[21] Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., & Cipriani, A. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. The Lancet, 394(10202), 939-951.

[22] Kadakia, A., Dembek, C., Heller, V., Singh, R., Uyei, J., Hagi, K., Nosaka, T., & Loebel, A. (2021). Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis. BMC psychiatry, 21(1), 249.

[23] Kishi, T., Ikuta, T., Matsuda, Y., Sakuma, K., Okuya, M., Mishima, K., & Iwata, N. (2021). Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. Molecular psychiatry, 26(8), 4146-4157.

[24] Li, R., Ou, J., Li, L., Yang, Y., Zhao, J., & Wu, R. (2018). The Wnt signaling pathway effector TCF7L2 mediates olanzapine-induced weight gain and insulin resistance. Frontiers in pharmacology, 9, 379.

[25] Li, S., Xu, C., Hu, S., & Lai, J. (2024). Efficacy and tolerability of FDA-approved atypical antipsychotics for the treatment of bipolar depression: a systematic review and network meta-analysis. European Psychiatry, 1-26.

[26] Liu, Y. (2018). Treatment of metabolic syndrome caused by olanzapine with modified Wendan Decoction. Jilin Journal of Chinese Medicine, 38(5), 540-544.

[27] Lu, W. W. (2021). A real-world study of the effects of lithium carbonate combined with olanzapine, risperidone, quetiapine on glucose and lipid metabolism in bipolar disorder Jining Medical College].

[28] Mijovic, A., & MacCabe, J. H. (2020). Clozapine-induced agranulocytosis. Annals of hematology, 99(11), 2477-2482.

[29] Ntalkitsi, S., Efthymiou, D., Bozikas, V., & Vassilopoulou, E. (2022). Halting the metabolic complications of antipsychotic medication in patients with a first episode of psychosis: how far can we go with the Mediterranean diet? A pilot study. Nutrients, 14(23), 5012.

[30] Oliva, V., Fico, G., De Prisco, M., Gonda, X., Rosa, A. R., & Vieta, E. (2025). Bipolar disorders: an update on critical aspects. The Lancet Regional Health–Europe, 48.

[31] Orzelska-Górka, J., Mikulska, J., Wiszniewska, A., & Biała, G. (2022). New atypical antipsychotics in the treatment of schizophrenia and depression. International Journal of Molecular Sciences, 23(18), 10624.

[32] Peng, T.-R., Chen, J.-A., Lee, J.-A., Hsing, C.-P., Lee, M.-C., & Chen, S.-M. (2024). The Optimal Dosage and Duration of Metformin for Prevention and Treatment of Antipsychotic-Induced Weight Gain: An Updated Systematic Review and Meta-Analysis. Schizophrenia Bulletin, sbae173.

[33] Petimar, J., Young, J. G., Yu, H., Rifas-Shiman, S. L., Daley, M. F., Heerman, W. J., Janicke, D. M., Jones, W. S., Lewis, K. H., & Lin, P.-I. D. (2024). Medication-induced weight change across common antidepressant treatments: a target trial emulation study. Annals of internal medicine, 177(8), 993-1003.

[34] Plans, L., Barrot, C., Nieto, E., Rios, J., Schulze, T., Papiol, S., Mitjans, M., Vieta, E., & Benabarre, A. (2019). Association between completed suicide and bipolar disorder: A systematic review of the literature. Journal of Affective Disorders, 242, 111-122.

[35] Prasad, F., De, R., Korann, V., Chintoh, A. F., Remington, G., Ebdrup, B. H., Siskind, D., Knop, F. K., Vilsbøll, T., & Fink-Jensen, A. (2023). Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin–a case series. Therapeutic Advances in Psychopharmacology, 13, 20451253231165169.

[36] Ren, C. L. (2020). Effect of acupuncture and moxibustion combined with self-made Zishen Shugan Decoction on prognosis of women with hyperprolactinemia induced by antipsychotic drugs. Clinical Journal of Chinese Medicine, 12(36), 70-71.

[37] Sapunar, Z., Munoz, N., & Vasquez, A. (2009). Risk of type 2 diabetes mellitus among users of atypical antipsychotic drugs or conventional treatment: systematic review and meta-analysis. Revista Medica de Chile, 137(11), 1417-1426.

[38] Shamshoum, H., Medak, K. D., McKie, G. L., Jeromson, S., Hahn, M. K., & Wright, D. C. (2023). Salsalate and/or metformin therapy confer beneficial metabolic effects in olanzapine treated female mice. Biomedicine & Pharmacotherapy, 168, 115671.

[39] SHEN, L., LING, Y., TANG, Y. P. . ( 2023). Effect of sodium valproate combined with olanzapine in the treatment of mania. Chinese Journal of Rural Medicine and Pharmacy, 30(11), 31-32.

[40] Stogios, N., Maksyutynska, K., Navagnanavel, J., Sanches, M., Powell, V., Gerretsen, P., Graff‐Guerrero, A., Chintoh, A. F., Foussias, G., & Remington, G. (2022). Metformin for the prevention of clozapine‐induced weight gain: a retrospective naturalistic cohort study. Acta Psychiatrica Scandinavica, 146(3), 190-200.

[41] Sun, F. L. (2023). Expert consensus on integrated traditional Chinese and western medicine diagnosis and treatment of metabolic syndrome caused by atypical antipsychotics in Zhejiang Province. . Zhejiang Clinical Medicine Journal, 25(7), 949-951.

[42] Vita, G., Nöhles, V. B., Ostuzzi, G., Barbui, C., Tedeschi, F., Heuer, F. H., Keller, A., DelBello, M. P., Welge, J. A., & Blom, T. J. (2024). Systematic review and network meta-analysis: Efficacy and safety of antipsychotics vs antiepileptics or lithium for acute mania in children and adolescents. Journal of the American Academy of Child & Adolescent Psychiatry.

[43] Voudris, K. A., Attilakos, A., Katsarou, E., Drakatos, A., Dimou, S., Mastroyianni, S., Skardoutsou, A., Prassouli, A., & Garoufi, A. (2006). Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy. Epilepsy research, 70(2-3), 211-217.

[44] Wu, R., Zhang, F., Gao, K., Ou, J., Shao, P., Jin, H., Guo, W., Chan, P., & Zhao, J. (2016). Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. Molecular psychiatry, 21(11), 1537-1544.

[45] Wu, R., Zhang, F., Gao, K., Ou, J., Shao, P., Jin, H., Guo, W., Chan, P., Zhao, J. (2023). Efficacy analysis of Jiawei Yueju Decoction in the treatment of metabolic syndrome caused by taking antipsychotics. World Journal of Complex Medicine, 9(1), 18-20.

[46] Yu, S. S., Zhu, Y. L., Wang, M., Xu, J. G. . (2019). Clinical observation on adjuvant treatment of hyperglycemia and dyslipidemia caused by atypical antipsychotic drugs with liuyu decoction Paper presented at the meeting of the 2019 Zhejiang Medical Association Toxicology Academic Conference, Hangzhou.

[47] Yuan, M., Xiao, Z.-L., Zhou, H.-Y., Rao, W., Huang, G., Nie, H.-B., Cao, W.-F., & Xu, R.-S. (2022). Bipolar disorder and the risk for stroke incidence and mortality: a meta-analysis. Neurological Sciences, 43(1), 467-476.

[48] Zareifopoulos, N., Bellou, A., Spiropoulou, A., & Spiropoulos, K. (2018). Prevalence of comorbid chronic obstructive pulmonary disease in individuals suffering from schizophrenia and bipolar disorder: a systematic review. COPD: Journal of Chronic Obstructive Pulmonary Disease, 15(6), 612-620.

[49] Zhang, Q. Z., Huang, C. H., Zheng, J. J., Ke, L. T., Chen, J. C. . (2023). Precision Exercise Prescription for Psychiatric Drug-induced Effects Intervention Effect of Drug-induced Obesity. China Health Standard Management, 14(2), 101–105.

[50] Zheng, Z. X. (2020). Effects of non-classical antipsychotics combined with affect stabilizers on metabolism in patients with bipolar disorder. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine, 30(1), 174-175.

[51] Zhu, P., Ji, C. F., Ji, F., Du, X., Yang, J. Y., Wu, J., Wang, S. L., Zhu, F., Lu, X. C., Kong, F. Z. . (2024). Effect of evidence-based cluster nursing on metabolism of female schizophrenics taking atypical antipsychotics. Journal of Psychiatry, 37(2), 133-137.